Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €82.72 EUR
Change Today -2.28 / -2.68%
Volume 374.4K
As of 10:52 AM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

merck kgaa (MRK) Snapshot

Open
€84.54
Previous Close
€85.00
Day High
€84.54
Day Low
€82.04
52 Week High
04/13/15 - €112.34
52 Week Low
10/16/14 - €65.52
Market Cap
36.0B
Average Volume 10 Days
747.6K
EPS TTM
€2.63
Shares Outstanding
129.2M
EX-Date
04/20/15
P/E TM
31.5x
Dividend
€1.00
Dividend Yield
1.21%
Current Stock Chart for MERCK KGAA (MRK)

Related News

No related news articles were found.

merck kgaa (MRK) Related Businessweek News

No Related Businessweek News Found

merck kgaa (MRK) Details

Merck Kommanditgesellschaft auf Aktien discovers, develops, manufactures, and markets pharmaceutical and chemical products worldwide. The company provides pharmaceutical and biological prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and cardiovascular and metabolic diseases; fertility drugs for every stage of the reproductive cycle; hypoallergenic products for specific immunotherapy and diagnosis of type 1 allergies; and biosimilars focusing on oncology and inflammatory disorders. It also manufactures and markets over-the-counter pharmaceuticals to address mobility, women’s and children’s health, cough and cold, and everyday health protection under the Neurobion, Bion, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brand names. In addition, the company offers life science tools and technologies for use in the research, development, and manufacture of biotechnological and pharmaceutical drug therapies, as well as in research and application laboratories. Further, it provides specialty chemicals that are used in various end products, including liquid crystals for displays; LED materials for lighting, as well as organic light-emitting diode materials for lighting and displays; functional materials for solar panels and energy solutions; effect pigments, as well as active ingredients and fillers for cosmetics, food, and pharmaceutical products; pigments and functional materials for coatings, printing, and plastics; and specialty chemical materials for the electronics industry. Merck Kommanditgesellschaft auf Aktien was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

40,192 Employees
Last Reported Date: 08/6/15
Founded in 1668

merck kgaa (MRK) Top Compensated Officers

Chairman of Executive Board and Chief Executi...
Total Annual Compensation: €6.6M
Group Chief Financial Officer and Member of E...
Total Annual Compensation: €1.2M
Chief Executive Officer of Life Science & Per...
Total Annual Compensation: €4.7M
Vice Chairman of Executive Board and Deputy C...
Total Annual Compensation: €6.0M
Head of Group Human Resources, General Partne...
Total Annual Compensation: €4.0M
Compensation as of Fiscal Year 2014.

merck kgaa (MRK) Key Developments

Merck Reports Earnings Results for the Second Quarter Ended June 2015; Reaffirms Earnings Outlook for the Full Year 2015

Merck KGaA reported earnings results for the second quarter ended June 2015. For the quarter, the company reported that net profit climbed 13.2% to EUR 343.4 million, compared with the EUR 303.3 million reported a year earlier. The increase in net profit was due to strong performance of all units and favorable exchange-rate effects. Earnings before interest and tax (EBIT) rose 13.7% to EUR 501 million. Adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) advanced 6.3% to EUR 899 million. Sales increased by 14.4% to EUR 3.2 billion. Organically, sales grew by 2.2%, but were further boosted by exchange rate effects of 10.2% and positive effects from the integration of AZ Electronic Materials. In earnings per share pre, the company saw increase from EUR 1.16 to EUR 1.30 of 12%, and this was predominantly due, due to the operating improvement and also to an increase or an improvement in the financial items. The company reiterated its full-year 2015 guidance for adjusted EBITDA of between EUR 3.45 billion and EUR 3.55 billion, up from the EUR 3.39 billion posted in 2014. Sales are expected to grow slightly organically and to be boosted further by currency effects of between 5% and 7%.

Group Communications Announces Management Changes

Isabel De Paoli (40), currently Head of Group Strategy, has been appointed Head of Group Communications effective March 9, 2016. In her new role, she will be responsible for all global communications at Merck. Walter Huber, who currently holds the position, will retire following the Group's annual earnings press conference on March 8, 2016. At that time, he will have just turned 60. On August 1, 2015, Isabel De Paoli will hand over operational responsibility for Group Strategy, which since the beginning of the year has also included Group Organization, to Heiko Schon (36). Isabel De Paoli will use the time until March to prepare for her new role. Isabel De Paoli joined Merck in August 2006 as Business Development Manager Chemicals and was appointed Head of Strategic Planning Oncology in 2009.

Merck KGaA to Invest USD 13.280 million in Rio De Janeiro Facility

Merck KGaA has announced a BRL 42 million (USD 13.280 million) investment to extend the Jacarepagua plant, in the Brazilian state of Rio de Janeiro. Merck plans to expand its production area by 30% from 4,900 square metres to 6,500 square metres. Merck targets production of 3.3 billion pills annually by 2018, up 80% on current capacity. Merck KGaA's extension plans are aimed at facilitating the development and manufacturing of eight biological drugs that are produced in co-operation with its Brazilian partner Bionovis. Additionally, Merck seeks to consolidate its position in other Latin American markets, notably Ecuador, Peru and Bolivia in the first phase, with exports set to grow by 30%. Merck also plans to enter markets in Central America, Argentina and Colombia.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:GR €82.72 EUR -2.28

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Johnson Matthey PLC 2,628 GBp -77.00
Koninklijke DSM NV €45.28 EUR -1.63
Solvay SA €102.15 EUR -2.75
Sumitomo Chemical Co Ltd ¥580.00 JPY -24.00
Yara International ASA 353.80 NOK -15.50
View Industry Companies
 

Industry Analysis

MRK

Industry Average

Valuation MRK Industry Range
Price/Earnings 32.2x
Price/Sales 3.0x
Price/Book 3.5x
Price/Cash Flow 9.6x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK KGAA, please visit www.merck.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.